title: The role of intravitreal chemotherapy for retinoblastoma.
abstract: Targeted therapy in retinoblastoma (RB) is widely accepted as the current management tool with an aim of increasing drug availability at the tumor location. Inevitably the effect is several times higher compared to systemic delivery of chemotherapeutic drugs and carries less systemic toxicity. Despite tremendous advancement in saving life, eye salvage in advanced RB especially with active vitreous seeds remains a challenge. The hypoxic environment of the vitreous and reduced vitreous concentration of the drugs delivered makes these tumor seeds resistant to chemotherapy. Direct delivery of chemotherapeutic drugs into the vitreous cavity aids to overcome these challenges and is progressively being accepted worldwide. However, intraocular procedure in RB was abandoned due to high risk of extraocular tumor dissemination. Recently, the forbidden therapeutic technique was re-explored and modified for safe use. Although eye salvage rate has tremendously improved after intravitreal chemotherapy (IVitC), retinal toxicity, and vision salvage are yet to be validated. In our preliminary report of intravitreal melphalan in 11 eyes, we reported 100% eye salvage and 0% recurrence with an extended 15 months mean follow-up. In this review, we analyzed published reports on IVitC in RB via PubMed, Medline, and conference proceedings citation index, electronic database search, without language restriction that included case series and reports of humans and experimental animal eyes with RB receiving IVitC.
authors.forename: Fairooz P
authors.initials: FP
authors.lastname: Manjandavida
authors.affiliation: Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.
authors.forename: Carol L
authors.initials: CL
authors.lastname: Shields
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006801:Humans; D058449:Intravitreal Injections; D019572:Retinal Neoplasms / Q000188:drug therapy*; D012175:Retinoblastoma / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents
references.citation: Arch Ophthalmol. 2002 Apr;120(4):460-4
references.pmid: 11934319
references.citation: Ophthalmology. 2014 Sep;121(9):1810-7
references.pmid: 24819859
references.citation: Int J Clin Oncol. 2004 Feb;9(1):31-5
references.pmid: 15162823
references.citation: Ophthalmic Genet. 2004 Mar;25(1):37-43
references.pmid: 15255113
references.citation: Acta Ophthalmol (Copenh). 1964;42(4):721-6
references.pmid: 4966433
references.citation: Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1979 Sep;211(3):205-13
references.pmid: 316288
references.citation: Ophthalmology. 1985 Dec;92(12):1763-7
references.pmid: 4088631
references.citation: Br J Ophthalmol. 1995 Feb;79(2):194-5
references.pmid: 7696247
references.citation: Nippon Ganka Gakkai Zasshi. 1995 Nov;99(11):1230-5
references.pmid: 8533651
references.citation: Arch Ophthalmol. 1996 Nov;114(11):1339-43
references.pmid: 8906024
references.citation: Arch Ophthalmol. 1996 Nov;114(11):1390-5
references.pmid: 8906030
references.citation: Acta Ophthalmol (Copenh). 1961;39:569-76
references.pmid: 13890561
references.citation: Ophthalmology. 2006 Dec;113(12):2276-80
references.pmid: 16996605
references.citation: Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3761-7
references.pmid: 17652749
references.citation: Ophthalmology. 2009 Mar;116(3):544-551.e1
references.pmid: 19157557
references.citation: Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1492-6
references.pmid: 18978345
references.citation: Invest Ophthalmol Vis Sci. 2009 Dec;50(12):5896-900
references.pmid: 19628744
references.citation: Arch Ophthalmol. 2011 Jun;129(6):732-7
references.pmid: 21320950
references.citation: Ophthalmology. 2011 Aug;118(8):1689, 1689.e1-6
references.pmid: 21813093
references.citation: Arch Ophthalmol. 2011 Nov;129(11):1399-406
references.pmid: 21670328
references.citation: Arch Ophthalmol. 2011 Nov;129(11):1492-4
references.pmid: 22084221
references.citation: Br J Ophthalmol. 2012 Apr;96(4):499-502
references.pmid: 22053101
references.citation: Br J Ophthalmol. 2012 Jun;96(6):881-3
references.pmid: 22328819
references.citation: Br J Ophthalmol. 2012 Aug;96(8):1073-7
references.pmid: 22368261
references.citation: Br J Ophthalmol. 2012 Aug;96(8):1078-83
references.pmid: 22694968
references.citation: Arch Ophthalmol. 2012 Oct;130(10):1268-71
references.pmid: 23044940
references.citation: Doc Ophthalmol. 2013 Feb;126(1):79-84
references.pmid: 23143758
references.citation: Eye (Lond). 2013 Feb;27(2):253-64
references.pmid: 22995941
references.citation: Exp Eye Res. 2013 Mar;108:103-9
references.pmid: 23333535
references.citation: Chin Med J (Engl). 2013;126(8):1587
references.pmid: 23595400
references.citation: Br J Ophthalmol. 2013 Oct;97(10):1231-6
references.pmid: 23740960
references.citation: Br J Ophthalmol. 2014 Mar;98(3):292-7
references.pmid: 24187047
references.citation: Ophthalmology. 2014 Feb;121(2):517-24
references.pmid: 24572675
references.citation: JAMA Ophthalmol. 2014 Mar;132(3):319-25
references.pmid: 24407202
references.citation: Int Ophthalmol. 2014 Jun;34(3):533-40
references.pmid: 24043335
references.citation: Ophthalmology. 2014 Jul;121(7):1453-60
references.pmid: 24656794
references.citation: JAMA Ophthalmol. 2014 Aug;132(8):936-41
references.pmid: 24789622
references.citation: Jpn J Clin Oncol. 2003 Dec;33(12):601-7
references.pmid: 14769836